Food and Drug Administration (FDA) issued an emergency use authorization for Abbott Laboratories’ (NYSE: ABT) BinaxNOWTM COVID-19 Ag. BinaxNOWTM COVID-19 Ag is a card-type tool for rapidly detecting COVID-19 infection in only 15 minutes. According to the press release, Abbott are going to distribute it for $5.
BinaxNOWTM COVID-19 Ag is one of antibody test kits based on lateral flow immunoassay. It utilizes the color reactions using metal particles. It does not require complicated operations and detects COVID-19 infection in only 15 minutes.
At the same time, Abbott also released a charge free mobile app NAVICATM. It allows healthcare providers to register the test results. This enables to display a temporary digital health pass on mobile phone. This makes it easier for companies and organizations to address social distances issues.
Following the announcement on August 26th, Abbott’s stock price surged more than 7% based on the closing price. According to Abbott’s 2020 Q2 financial results, its revenue and operating income were decreased mainly due to postponement of unnecessary surgeries etc. But the revenue for rapid diagnostics including those for detecting COVID-19 infection increased by 9.6%.
- Watanabe & Brothers’ Investment is holding shares of Abbott Laboratories.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.